drugset

drugset / Trial / NCT05458180

CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma

NCT05458180 ↗

Phase 1 Unknown 18 enrolled Tianjin Medical University Cancer Institute and Hospital CSPC Ouyi Pharmaceutical Co., Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, single arm, multicenter, dose-escalation clinical study to evaluate the safety and efficacy of CMOEP in patients with untreated Peripheral T-cell Lymphoma.

Timeline

Start: 2022-07-07
Primary completion: 2024-12-15
Completion: 2025-04-15

Publications

Yu J, Sun X, Gao G, Yu L, Wang J, Qiu L, Qian Z, Li W, Zhang H. CMOEP regimen in the treatment of untreated peripheral T-cell lymphoma: a multicenter, single-arm, phase I study. Front Immunol. 2025 Apr 11;16:1551723. doi: 10.3389/fimmu.2025.1551723. eCollection 2025.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mitoxantrone	Small molecule	15 mg/m2	Intravenous
Subject	Mitoxantrone	Small molecule	18 mg/m2	Intravenous
Subject	Mitoxantrone	Small molecule	20 mg/m2	Intravenous
Background	Cyclophosphamide	Other / unclassified	750 mg/m2	Intravenous
Background	Etoposide	Small molecule	60 mg/m2	Intravenous
Background	Prednisone	Other / unclassified	100 mg	Oral
Background	Vincristine	Small molecule	1.4 mg/m2	Intravenous

Indications